More French drug price cuts in store as 'stability programme' gets green light
This article was originally published in SRA
The French pharmaceutical industry is again under the hammer. Parliament has passed a package of measures including proposals to slice €10bn of healthcare spending over the 2015-17 period – some €3.5bn of which will affect medicines, and probably medical devices – in the form of selected price cuts, together with moves to increase the market share of generics.
You may also be interested in...
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.
At current rates, not enough coronavirus vaccines will be manufactured in 2021 or even 2022 to meet global demand or achieve global population immunity, according to a new dataset that monitors vaccine supply agreements around the world.